Symbiotec Pharmalab Ltd Growth Catalysts - SOIC x StockScans Report

as of Nov 2026

  1. DCV injectables US deal - Knovea signed an exclusive long-term agreement on 30 Sep 2026 with a leading global pharma company for two dual-chamber vial injectables addressing a \~$300 mn US market; the first ANDA was filed in September 2026 with priority review and a July goal date. Milestone income of ₹53 cr was booked in Q2 FY27 with similar amounts expected yearly, and supply revenues start next fiscal year once approval and FDA inspection land in late calendar 2027.
  2. European alternate protein CDMO - A 10-year take-or-pay agreement signed 6 Nov 2026 reserves dedicated Ujjain fermentation capacity for a European alternative-protein maker backed by two MNCs, with Phase 0 production starting this fiscal year from the existing 100 KL. Phase 1 toll fees alone run into a few tens of millions of dollars and should sit in the P&L by FY28-29, within a \~₹1,000 cr phased project partly funded by the customer.
  3. US alternate protein contract - A 10-year take-or-pay contract with a US alternate-protein company is in place, with commercial batches expected in Q1 FY28 and the first product launch around April/May 2027. Management expects the customer to discuss multiples of the committed capacity once the product ships, with contracted fees escalating with inflation each year.
  4. Insulin and GLP-1 biologics - A 5-year take-or-pay contract for insulin drug substance is signed, with commissioning and validation batches expected in Q4 FY27 and sales from mid FY28 to an Indian partner, on a little over ₹100 cr of capex. Half the dedicated 14 KL fermentation capacity is reserved for GLP-1s and insulin analogs like Glargine and Aspart, where a manufacturing and supply agreement is already in place and validation batches are underway.
  5. Steroid API core growth - Q2 FY27 API revenue grew 16% YoY to ₹227 cr at 60%+ gross margins, and management guides to high single-digit (sometimes low double-digit) growth with visibility for several years. With utilization at only 70-80% of the ₹650 cr API asset base and 44 US DMFs filed, volume growth needs little new capital.
  6. Ujjain fermentation platform build-out - The 750 KL Phase 1 expansion at the now 72-acre Ujjain site starts construction in Q3 FY27 with a 12-15 month build, alongside advanced-stage discussions with around 4 potential customers each needing around a million litres. First small CDMO revenues arrive in Q4 FY27, with a significant chunk of CDMO revenue expected in FY28 under take-or-pay terms.
  7. Vegan Vitamin D3 launch - The vegan D3 plant should be finished and qualified by end of this fiscal year, with nutraceutical and veterinary sales starting early next fiscal year. The product currently sells at 3-4 times the price of animal-derived D3, and Symbiotec's process lets it compete even at animal-D3 price points.